Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer

Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada

Global Hand Washing Day: Sir HN Reliance Foundation Hospital initiates awareness campaign for underprivileged students in Mumbai

hey were educated about the 7- step hand-washing technique trainings

USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis

Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials

Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData

Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024

Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules

Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.

Boehringer Ingelheim’s treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program